GSK published the AI Asset Register Part 2: Classification in the AI Auditor series.
Public source
Publisher name
Public post
New on the AI Auditor: The AI Asset Register Part 2: Classification. It is part two of a four-part series on building an AI asset register, and it answers the question p…
Company
GSK
- Industry
- Pharmaceutical Manufacturing
- Location
- London, GB
- Company size
- 10,001+ employees
About GSK
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
See moreLatest activity
Latest activity from GSK
39 signals
Presence & Recognition
GSK is attending the ERSCongress to meet global experts and shape the future of respiratory medicine with its pipeline targeting key inflammatory pathways of respiratory disease with longer-acting solutions.
Research & Knowledge
GSK published a new Custom Content article from The Wall Street Journal by Hesham A. Abdullah, MD, MSc and Chris Sheldon, PhD, sharing their approach to oncology business development.
Research & Knowledge
GSK accelerated research programmes are looking to target multiple inflammatory pathways, including TSLP and IL-33, to build a diverse portfolio for COPD patients.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Orion GXP Consulting
Orion GXP Consulting published an article by Nick Corcoran exploring a practical use case for AI within pharmaceutical Quality Assurance using AI as a tool to support document review, challenge content, and identify potential gaps.
Research & Knowledge
PharmaLex
PharmaLex published a review of 20+ current guidance documents on AI in GxP environments, including FDA, EMA, MHRA, and PIC/S guidance.
Research & Knowledge
PSI CRO
PSI CRO published a white paper examining the operational reality of agentic AI in clinical development, including how AI is applied across feasibility, trial management, decision support, and execution oversight in complex global studies.
Research & Knowledge
AstraZeneca
AstraZeneca published an article in MIT Technology Review exploring how AI is embedded across biologics discovery to identify potential new biologics for development in weeks instead of months.
Research & Knowledge
Pfizer